ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 0381 • ACR Convergence 2020

    Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis

    Ana-Maria Orbai1, Philip Mease2, Philip Helliwell3, Oliver FitzGerald4, Mohamed Bedaiwi5, Dona Fleishaker6, Rajiv Mundayat6 and Pamela Young7, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 5Division of Rheumatology, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Dactylitis, a hallmark of psoriatic arthritis (PsA), is a uniformly diffuse and sometimes painful swelling of the fingers and/or toes.1 Up to 50% of…
  • Abstract Number: 0873 • ACR Convergence 2020

    Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Charlie Lovan5 and Alexis Ogdie6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., North Chicago, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
  • Abstract Number: 1372 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement

    Atul Deodhar1, Roberto Ranza2, Fabiana Ganz3, Tianming Gao4, Jaclyn K Anderson4 and Andrew Östör5, 1Oregon Health & Science University, Portland, OR, 2Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, 3AbbVie Inc., Baar, Switzerland, 4AbbVie Inc., North Chicago, IL, 5Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy for the treatment of AS in patients (pts) who were NSAID inadequate responders (IR).1 Pts with psoriatic arthritis (PsA)…
  • Abstract Number: 1718 • ACR Convergence 2020

    Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort

    Joanna Kedra1, David Hajage1, Alexandre Lafourcade1, Bernard Combe2, Maxime Dougados3 and Bruno Fautrel4, 1Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, 2University of Montpellier, Montpellier, France, 3Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, 4Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France

    Background/Purpose: Long-term observational studies on the prediction of structural damage progression (SDP) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely…
  • Abstract Number: 1998 • ACR Convergence 2020

    Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis

    Camille Roubille1, Amandine Coffy2, Nathalie Rincheval2, Jean Pierre Daures2, René-Marc Flipo3, Maxime Dougados4 and Bernard Combe5, 1CHU LAPEYRONIE, Montpellier, France, 2INSERM, Montpellier, France, 3Univ-Lille, CHU Lille, department of rheumatology, Lille, France, 4Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, 5University of Montpellier, Montpellier, France

    Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…
  • Abstract Number: 0230 • ACR Convergence 2020

    Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial

    Nora G. Singer1, Shalini V. Mohan2, Jeffrey Yourish3, Jian Han2, Michael Edwardes4 and Margaret Michalska3, 1Case Western Reserve University and MetroHealth System, Cleveland, 2Genentech, South San Francisco, CA, 3Genentech, Inc., South San Francisco, 4Everest Clinical Research, Ontario, Canada

    Background/Purpose: In patients with rheumatoid arthritis (RA), subcutaneous tocilizumab (TCZ-SC) is administered every 2 weeks (q2w) or every week (qw), based on the patient’s weight…
  • Abstract Number: 0393 • ACR Convergence 2020

    Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS)

    Boyang Zheng1, Mianbo Wang2, Kerry McKenna3, Lee Shapiro4, Robert Spiera5, Richard Silver6, Mary Ellen Csuka7, Frank van den Hoogen8, David Robinson9, Laura Hummers10, Thomas Krieg11, Francesco Del Galdo12, Niall Jones13, Nader Khalidi14, Alessandra Vacca15, Jessica Gordon16, John Pauling17 and Murray Baron18, 1McGill University, Montreal, Canada, 2Lady Davis institute for Medical Research, Montreal, QC, Canada, 3Jewish General Hospital, McGill University, Montreal, Canada, 4Albany Medical College, Stillwater, NY, 5Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, 6Medical University of South Carolina, Charleston, 7Medical college of Wisconsin, Milwaukee, WI, 8Sint Maartenskliniek, Nijmegen, Netherlands, 9University of Manitoba, Winnipeg, MB, Canada, 10Johns Hopkins Univerisity, Ellicott City, MD, 11University of Cologne, Cologne, Germany, 12Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 13Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 14McMaster University, Hamilton, ON, Canada, 15University Hospital of Cagliari, Monserrato, Italy, 16Hospital for Special Surgery, New York, NY, 17Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 18Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Diffuse cutaneous Systemic Sclerosis (dcSSc) is a morbid disease involving the skin and internal organs. The American College of Rheumatology has provisionally approved a…
  • Abstract Number: 0884 • ACR Convergence 2020

    Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Patrick Zueger4 and Alexis Ogdie5, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
  • Abstract Number: 1417 • ACR Convergence 2020

    Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study

    Sara Thietart1, Guillaume Beinse2, Perrine Smets3, Alexandre Karras4, Carole Philipponnet5, Jean-François Augusto6, Khalil El Karoui7, Rafik Mesbah8, Dimitri Titeca Beauport9, Mohamed Hamidou10, Pierre-Louis Carron11, Julien Campagne12, Karim Sacre13, Pascal Cohen1, Eric Liozon14, Claire Blanchard-Delaunay15, Alex Kostianovsky16, Christian Pagnoux17, Luc Mouthon1, Loïc Guillevin18, Benjamin Terrier1 and Xavier Puéchal for the French Vasculitis Study Group1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 2Inserm UMR 1138, Centre de Recherche des Cordeliers, Paris, France, 3Department of Internal Medicine, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Gabriel-Montpied, Clermont Ferrand, France, 4Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, 5Department of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont Ferrand, France, 6Department of Nephrology-Dialysis-Transplantation, CHU Angers, Angers, France, 7Department of Nephrology and Transplantation, Hôpital Universitaire Henri-Mondor, Creteil, France, 8Department of Nephrology, CH Boulogne-sur-Mer, Boulogne-Sur-Mer, France, 9Department of Nephrology, Amiens University Medical Center, Amiens, France, 10Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, 11Department of Nephrology-Dialysis-Transplantation, CHU Grenoble-Alpes, Grenobles, France, 12Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, 13Département de Médecine Interne, Hôpital Bichat, APHP, Paris, France, 14Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, 15Department of Internal Medicine, CH, Niort, France, 16Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aeres, Argentina, 17Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 18Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France

    Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…
  • Abstract Number: 1725 • ACR Convergence 2020

    An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice

    Elston He1, Pratyusha Yalamanchi2, William Arnold3 and Erin Arnold4, 1Synovium, Inc., Philadelphia, PA, 2Michigan Medicine, Ann Arbor, MI, 3Retired, Wilmette, IL, 4Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL

    Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…
  • Abstract Number: 2007 • ACR Convergence 2020

    Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate

    Peter Taylor1, Bryan Downie2, Emon Elboudwarej2, Sam Kim2, Angie Hertz2, Amer Mirza2, Jeff Siegel3, Rachael Hawtin2 and Jinfeng Liu2, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City, 3Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA).…
  • Abstract Number: 0247 • ACR Convergence 2020

    Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus

    Ji-Won Kim1, Ju-Yang Jung1, Hyoun-Ah Kim1 and Chang-Hee Suh1, 1Ajou university school of medicine, Suwon, Republic of Korea

    Background/Purpose: This study aimed to examine the frequency and risk factors of complications during pregnancy in women with systemic lupus erythematosus (SLE).Methods: The medical records…
  • Abstract Number: 0427 • ACR Convergence 2020

    Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis

    Emily Rose1, Marcela Ferrada1, Kaitlin Quinn2, Wendy Goodspeed1, Laurent Arnaud3 and Peter C. Grayson4, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, BETHESDA, MD, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 3Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Physician global assessment (PhGA) is a measure…
  • Abstract Number: 0886 • ACR Convergence 2020

    Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis

    Atul Deodhar1, Andrew Östör2, Anna Maniccia3, Fabiana Ganz4, Tianming Gao3, Alvina D. Chu5 and Denis Poddubnyy6, 1Oregon Health & Science University, Portland, OR, 2Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 3AbbVie Inc., North Chicago, IL, 4AbbVie Inc., Baar, Switzerland, 5AbbVie, North Chicago, IL, 6Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
  • Abstract Number: 1457 • ACR Convergence 2020

    Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis

    Sai kumar Dunga1, Chengappa G Kavadichanda2 and VS Negi2, 1Jawaharlal institute of postgraduate medical education and research, puducherry, India, 2Jawaharlal institute of postgraduate medical education and research, Puducherry, Puducherry, India

    Background/Purpose: Inflammatory myositis are heterogenous group of diseases affecting skeletal muscles and multiple different organs. Assessing improvement in disease activity is done by Manual muscle…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology